Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Common Equity: 2019-2025

Historic Common Equity for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to -$1.7 million.

  • Biodesix's Common Equity fell 106.18% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 106.18%. This contributed to the annual value of $20.9 million for FY2024, which is 355.81% up from last year.
  • Biodesix's Common Equity amounted to -$1.7 million in Q3 2025, which was down 251.32% from $1.1 million recorded in Q2 2025.
  • Biodesix's Common Equity's 5-year high stood at $36.4 million during Q1 2021, with a 5-year trough of -$7.0 million in Q2 2023.
  • Moreover, its 3-year median value for Common Equity was $4.5 million (2023), whereas its average is $8.2 million.
  • The largest annual percentage gain for Biodesix's Common Equity in the last 5 years was 2,026.49% (2024), contrasted with its biggest fall of 220.92% (2024).
  • Biodesix's Common Equity (Quarterly) stood at $19.7 million in 2021, then grew by 4.46% to $20.6 million in 2022, then crashed by 77.77% to $4.6 million in 2023, then soared by 355.81% to $20.9 million in 2024, then slumped by 106.18% to -$1.7 million in 2025.
  • Its Common Equity stands at -$1.7 million for Q3 2025, versus $1.1 million for Q2 2025 and $11.1 million for Q1 2025.